home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited From 12/22/22

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - Okyo stock rises 10% on FDA nod to start trial of dry eye disease therapy

The U.S. Food and Drug Administration (FDA) cleared Okyo Pharma's ( NASDAQ: OKYO ) investigational new drug (IND) to start a phase 2 trial of OK-101 for treating dry eye disease (DED). The London-based company said that the FDA previously agreed with its plans for designating...
OKYO - OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) --...

OKYO - OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, a...

OKYO - OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that i...
OKYO - OKYO Pharma Limited - PDMR dealing

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces tha...

OKYO - OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-...

OKYO - OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Monday, November 14 th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology bio-pharmaceutical company focusing on the discove...
OKYO - OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference

New York, New York--(Newsfile Corp. - October 20, 2022) - OKYO Pharma Ltd. (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, will be participating i...

OKYO - OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO,...

OKYO - OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

NEW YORK, NY / ACCESSWIRE / September 8 2022 / OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Ja...
Previous 10 Next 10